GCCA
14.3.2023 14:02:00 CET | Business Wire | Press release
Start-ups from around the world can play a leading role in helping an essential global industry in its efforts to cut CO2 emissions and help solve the climate challenge. They are being invited to apply for the Innovandi Open Challenge, an exciting international partnership programme, run by the Global Cement and Concrete Association (GCCA) and its member companies across the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005357/en/
Applications for the 2023 GCCA Innovandi Open Challenge are now open (Graphic: Business Wire)
Applicants are being asked to work on the development of new materials and ingredients for low carbon concrete – a major step towards the ultimate goal of net zero concrete.
Innovation can help further unlock the delivery of low carbon concrete by reducing the amount of clinker used - the carbon intensive element of cement - or by using the most cutting-edge manufacturing processes. Alternative materials, including construction and demolition waste, can result in much lower CO2 emissions than concrete made in the traditional method, as well as reduce the need to use virgin raw materials.
The global challenge matches start-up companies with some of the world’s leading cement and concrete manufacturers, who operate in almost every country across the world, to work on initiatives to cut emissions and pioneer environmental change across the industry.
The GCCA and its members account for 80% of global cement production capacity outside of China, as well as some key Chinese manufacturers. Member companies have committed to reducing and ultimately eliminating CO2 emissions in concrete (which currently account for around 7% globally), through implementation of the GCCA’s Concrete Future 2050 Net Zero Roadmap – the first heavy industry to set out such a detailed plan.
The launch follows the success of last year’s first ever Innovandi Open Challenge, which saw cement companies partnering with six start-ups, with a strong focus on carbon capture and utilisation projects. Three of those projects have already gone to pilot stage.
Thomas Guillot, Chief Executive of the GCCA, said:
“We’re calling on the best and the brightest from around the world to join us in the urgent fight to limit global warming and help towards delivering the great prize of net zero concrete. If you are a start up from Austria to Australia, from Brazil to Bangladesh, with an innovative idea or technology, then we want to hear from you.”
“Concrete is the second most used substance on earth after water and is a vital part of our modern infrastructure. The GCCA and all our members are working hard to reduce emissions. And start-ups can play a big role in helping us to do that.”
Start-ups can find more information and apply to take part in the Innovandi Open Challenge by going to the GCCA Open Challenge webpage:
https://gccassociation.org/innovandi/openchallenge/oc2023
Those companies who are accepted for this year’s Innovandi Open Challenge, will gain unique access to industry plants, labs, key networks and the expertise and infrastructure of the GCCA’s 40 members from around the world. They will also receive guidance from the GCCA and its members to help them with the development of new technology and business cases.
Claude Loréa, GCCA Cement Director and Innovation Lead said:
“We’ve already seen some remarkable progress from those start-ups who’ve been working with our members on the first Innovandi Open Challenge, with several projects already in the pilot stage. This year’s theme, low carbon concrete, is equally challenging. To succeed, we need products which are affordable, scalable, and easily adopted. Good luck to all this year’s applicants. We look forward to working with those selected.”
Natalie Giglio is Senior Business Development Associate, at Carbon Upcycling Technologies in Canada, which took part in the first Innovandi Open Challenge. She encourages all start-ups interested in working on net-zero initiatives to apply:
"The Innovandi program is specifically designed to foster collaboration among the largest global cement producers, and start-ups, which is an opportunity unique to this challenge. Our initiative focused on validating materials at the lab scale, and now the results have set a foundation for further collaboration and project development.”
/ Ends
Notes to editors:
The Innovandi Open Challenge is open to applicants from 14th March 2023, with applications closing on 30th May 2023.
For more information click here:
Additional quotes from start-ups which have taken part in the 1st Innovandi Open Challenge:
Carbon BioCapture is based in the USA and has patented technology for CO2 capture using microalgae (microscopic algae invisible to the naked eye.) CEO Andrea Irarrazaval said: “It has been a great opportunity and an honour for Carbon BioCapture (CBC) to be selected in GCCA's Open Challenge global programme… Participation provides valuable means for tech start-ups to access, obtain growth assistance, and help to demonstrate their technology potential to the critical cement and concrete global industry."
CarbonOrO, based in the Netherlands, specializes in carbon capture technology using unique bi-phasic amine. Spokesperson Jan Hoppenbrouwers said: “There is a lot of talk about carbon capture, utilisation and storage but worldwide, we need to accelerate the number of pilots and move towards commercial scale roll-out. GCCA members and their consortia’s joined efforts have all the characteristics to change this. So, our advice, participate in this challenge.”
Coomtech based in the UK, has developed a low energy, low cost drying technology using managed turbulent air, creating kinetic energy to remove moisture. Founder Chris Every said: “Coomtech took part in the Innovandi Open Challenge to showcase its technology at a global level to the cement and concrete industry. Innovandi has been highly supportive and is commercially attuned to new technologies. The connections the program makes are an excellent springboard for emerging technology businesses focused on the vital cement and concrete sector.”
Fortera, based in the USA, uses technology to capture CO2 emissions from cement plants, combining it with calcium oxide to make reactive calcium carbonate. Vice President Kas Farsad, said: “The Innovandi Open Challenge platform allowed Fortera to engage multiple cement players simultaneously and really dig into not just industry pain points, but brainstorm on solutions with the broader industry in mind. Whether you're looking to launch a pilot plant or to validate a commercial offering, you'll get a committed consortium of GCCA members supporting your process."
MOF Technologies, based in the UK, is using modern sorbents called metal-organic frameworks (MOFs) to engineer a filtration system to capture and remove CO2 from flue gas. Conor Hamill, Co-CEO said: “Having developed a carbon capture system that overcomes the traditional adoption barriers of energy and cost, we are thrilled to have had the opportunity to collaborate with GCCA members to bring our technology to the field. We are currently working with an innovative consortium to pilot our ultra-efficient Nuada technology which will validate its potential to provide the industry with a scalable low-cost carbon capture solution.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005357/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
